Nov 15 (Reuters) - Syndax Pharmaceuticals Inc

Nov 15 (Reuters) - Syndax Pharmaceuticals Inc Sndx.o:

Syndax Announces FDA Approval of Revuforj® (Revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients With Relapsed or Refractory Acute Leukemia With a Kmt2a Translocation
Syndax Pharmaceuticals Inc - Revuforj 110 and 160 Mg Tablets Expected to Be Available for Order in U.S. in November
Syndax Pharmaceuticals - 25 Mg Revuforj Tablets Expected to Be Commercially Available in Late Q1 or Early Q2 of 2025
Syndax Pharmaceuticals: Before Commercial Availability of 25 Mg Tablets, Oral Solution of Revumenib to Be Available Through Expanded Access Program

Source Text: Id:Npn3Nsdvka

Further Company Coverage: Sndx.o

((Reuters.briefs@Thomsonreuters.com;))

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Risk Disclaimer